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In their recent interesting observational cohort study the authors1 compared the rate of subsequent 
bowel resection in patients with Crohn’s disease (CD) who had stopped anti-TNF therapy before 12 
months compared with those continuing for 12 months or longer. They included 1856 patients, 
1260 treated with adalimumab and 596 with infliximab. Twelve months after starting therapy, 65% 
were still receiving anti-TNF, 27% had been taken off the drug and 7% had undergone early bowel 
resection and were excluded from further analysis. The cumulative proportion of first bowel 
resection was 25% at 6 years, similar among patients treated <12 months and those with treatment 
maintenance ≥12 months. Hence, based on these data, biologics did not modify the natural history 
of CD. 
The authors tried to explain this surprising result. They hypothesized that the similar surgical rates 
could be derived from the fact that the cohort maintained on anti-TNF for more than 12 months 
most likely included patients with the most severe disease type. As this was a register-based study 
the authors did not have details on why the patients stopped the anti-TNF. The authors reasonably 
speculated that the patients taken off the drug before 12 months were those who either did not 
respond to or were intolerant to anti-TNF. Given the relatively low rate of mucosal healing reported 
with anti-TNF e.g. 28% maintained mucosal healing with infliximab2 it is unlikely that many 
patients stopped the anti-TNF within 12 months because they had achieved mucosal healing.  
Another possible explanation is that treatment with biologics may often be introduced too late, 
when structural bowel damage is already evident. To limit this bias, the authors correctly excluded 
patients who underwent early bowel resection; furthermore, the duration of CD before the start of 
the anti-TNF affected neither treatment retention nor early bowel resection at 12 months.  
They also report that concomitant use of immunomodulators did not impact on risk for resection. 
We wonder though whether use of immunomodulators or of systemic corticosteroids after cessation 




Further data about immunosuppressant and corticosteroid use, which might well have been different 
between early anti-TNF stoppers (who would likely have needed an alternative to anti-TNF) and 
those who continued, would be interesting to allow further analysis of this intriguing result. 
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